Skip to main content

Agora
Sign in

Senate bill · S. 882 (119th Congress)

Patients Before Middlemen Act

U.S. Senate

Latest action Mar 6, 2025

Sponsor: Marsha Blackburn (U.S. Senator for Tennessee, Republican)

Follow

Following needs an Agora account. You will sign in first, then come back to this page.

From Congress.gov and official rosters. This record was last updated Aug 1, 2026. About our data

Summary

Patients Before Middlemen Act This bill establishes certain standards and reporting requirements for prescription drug plan (PDP) sponsors, pharmacy benefit managers (PBMs), and pharmacies under the Medicare prescription drug benefit and Medicare Advantage. Specifically, the Centers for Medicare & Medicaid Services (CMS) must develop reasonable and relevant standards for contracts between PDP sponsors and pharmacies. The CMS must seek input from interested stakeholders when developing these standards. PDP sponsors are subject to civil penalties for violating these standards; PBMs must reimburse PDP sponsors for civil penalties that result from their responsibilities. The bill also requires the CMS to report periodically on essential retail pharmacies (i.e., pharmacies that serve as the only pharmacy within a certain radius) with respect to costs, contracts, and other specified information, particularly in relation to other types of pharmacies. Additionally, PBMs may not receive any income other than flat, bona fide service fees. PBMs must turn over any excess amounts they receive to PDP sponsors; PDP sponsors must turn over these amounts to the CMS. In addition, PBMs must report to PDP sponsors and to the CMS an itemized list of prescription drugs that were dispensed during the previous year and related data about costs, claims, affiliated pharmacies, and other specified information. PDP sponsors may audit PBMs to ensure compliance with these requirements and must annually certify their compliance; PBMs are responsible for any associated civil penalties for violations. The bill's changes generally apply beginning in 2028.

Summary from the Congressional Research Service. How we handle summaries

Where it stands

Assigned to a committee for review.

  1. Introduced
  2. In committee
  3. Up for a vote
  4. Passed one chamber
  5. Passed
  6. Enacted

Committee

Senate Committee on Finance · U.S. Senate

Your position on this bill

Choose the position closest to yours. You'll sign in or create an account to save it.

Sign in or create an account to give your position

Cosponsors

7

Cosponsors listed on Congress.gov, shown A to Z.

  • Democratic4
  • Republican3

This bill has cosponsors from more than one party.

Shown in neutral colors by design; Agora is non-partisan.

Related bills

As identified by Congress.gov.

Full history

  1. Mar 6, 2025

    Introduced

    Introduced in U.S. Senate

    U.S. Senate

  2. Mar 6, 2025

    Referred to committee

    Read twice and referred to the Committee on Finance.

  3. Mar 6, 2025

    Referred to committee

    Read twice and referred to the Committee on Finance.

  4. Mar 6, 2025

    Referred to committee

    Read twice and referred to the Committee on Finance.

Read the record